Theranostics (or theragnostics 6) uses a diagnostic examination to determine if a patient may benefit from a specific therapeutic drug and thus couples the therapy with diagnostic information specific for the intended target 2.
Theranostics promises improved patient selection for therapy on the basis of specific molecular features of disease, using information from pharmacogenetics, proteomics, and biomarker profiling to provide a cost-effective targeted management protocol thereby generating a custom-made treatment plan based on the uniqueness of every individual 3.
Selection of patients for any radionuclide therapy is achieved by the demonstration of adequate uptake in all involved tumor sites in order to deliver a radiation absorbed dose sufficient to accomplish therapeutic goals of symptom or disease control.4
History and etymology
The term “theranostic” was coined in 2002 by John Funkhouser 1 and is a portmanteau of the two terms - therapeutics and diagnostics.
- 1. Funkhouser, J. (2002) Reintroducing pharma: Theranostic revolution. Curr. Drug Discovery
- 2. Daniel Y. Lee, King C. P. Li. Molecular Theranostics: A Primer for the Imaging Professional. (2012) American Journal of Roentgenology. doi:10.2214/AJR.11.6797
- 3. Jeelani S, Reddy RC, Maheswaran T, Asokan GS, Dany A, Anand B. Theranostics: A treasured tailor for tomorrow. (2014) Journal of pharmacy & bioallied sciences. 6 (Suppl 1): S6-8. doi:10.4103/0975-7406.137249 - Pubmed
- 4. Sneha S. Kelkar, Theresa M. Reineke. Theranostics: Combining Imaging and Therapy. (2011) doi:10.1021/bc200151q
- 5. Turner JH. Recent advances in theranostics and challenges for the future. (2018) The British journal of radiology. 91 (1091): 20170893. doi:10.1259/bjr.20170893 - Pubmed
- 6. Frangos S, Frangos BJ, Frangos. Why should we be concerned about a "g"?. (2019) European journal of nuclear medicine and molecular imaging. doi:10.1007/s00259-018-4204-z - Pubmed